Zhu XX, et al. - In Chinese patients with type 2 diabetes (T2D), the researchers examined the pharmacokinetics and pharmacodynamics of a dual-acting glucokinase activator, dorzagliatin, and its safety, tolerability and effect on pancreatic β-cell function. An aggregate of 24 T2D patients was chosen, utilizing a set of predefined clinical biomarkers, and was randomized to receive dorzagliatin 75 mg twice or once daily (BID, QD respectively) for 28 days. According to predefined biomarkers selection, dorzagliatin treatment for 28 days in Chinese T2D patients resulted in significant improvement in β-cell function and glycaemic control. They reported that the safety and pharmacokinetic profile of dorzagliatin supports a subsequent Phase II trial design and continued clinical development.